IR@PKUHSC  > 北京大学第三临床医学院  > 血液内科
学科主题临床医学
Genomic landscape and prognostic analysis of mantle cell lymphoma
Yang, Ping; Zhang, Weilong; Wang, Jing; Liu, Yuanyuan; An, Ran; Jing, Hongmei
通讯作者Jing, Hongmei(1)
刊名CANCER GENE THERAPY
2018-06-01
DOI10.1038/s41417-018-0022-5
25期:5页:129-140
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biotechnology & Applied Microbiology ; Oncology ; Genetics & Heredity ; Medicine, Research & Experimental
研究领域[WOS]Biotechnology & Applied Microbiology ; Oncology ; Genetics & Heredity ; Research & Experimental Medicine
关键词[WOS]CONTRALATERAL BREAST-CANCER ; MOLECULAR PATHOGENESIS ; MUTATION CARRIERS ; SOMATIC MUTATIONS ; ADVANCED-STAGE ; TP53 MUTATION ; COPY NUMBER ; PERSPECTIVES ; DISCOVERY ; IMPACT
英文摘要

To gain insight into the molecular pathogenesis of patients with mantle cell lymphoma (MCL), next-generation whole-exome sequencing of 16 MCL patients was performed. We identified recurrent mutations in genes that are well known to be functionally relevant in MCL, including ATM (37.5%), TP53 (31.3%), WHSC1 (31.3%), CCND1 (18.8%), NOTCH2 (6.3%), and CDKN2A (6.3%). We also identified somatic mutations in genes for which a functional role in MCL has not been previously suspected. These genes included CCDC15, APC, CDH1, S1PR1, ATRX, BRCA2, CASP8, and NOTCH3. Further, we investigated the prognostic factors associated with MCL from clinical, pathological, and genetic mutations. Mutations of TP53 (P = 0.021) was a significant prognostic factor with shorter overall survival (OS). Although there was no statistical difference, the median survival time of patients with WHSC1 mutations was shorter than those without mutations (P = 0.070). Mutations in ATM and CCND1 had no prognostic value (P = 0.552, 0.566). When adjusted for MCL International Prognostic Index (MIPI) or combined MCL-International Prognostic Index (MIPI-c), TP53 and WHSC1 mutations were the most important prognostic factors in MCL (P < 0.05). Our data provide an unbiased view of the landscape of mutations in MCL and commend that all patients benefit from mutations of TP53 and WHSC1 at diagnosis, in addition to MIPI and MIPI-c score.

语种英语
WOS记录号WOS:000437202000004
通讯作者邮箱jinghm70481@126.com
第一作者单位Peking Univ, Hosp 3, Lymphoma Res Ctr, Dept Hematol, Beijing 100191, Peoples R China
通讯作者单位Peking Univ, Hosp 3, Lymphoma Res Ctr, Dept Hematol, Beijing 100191, Peoples R China
ISSN0929-1903
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/142461
专题北京大学第三临床医学院_血液内科
北京大学护理学院_护理学院
作者单位Peking Univ, Hosp 3, Lymphoma Res Ctr, Dept Hematol, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Yang, Ping,Zhang, Weilong,Wang, Jing,et al. Genomic landscape and prognostic analysis of mantle cell lymphoma[J]. CANCER GENE THERAPY,2018,25(5):129-140.
APA Yang, Ping,Zhang, Weilong,Wang, Jing,Liu, Yuanyuan,An, Ran,&Jing, Hongmei.(2018).Genomic landscape and prognostic analysis of mantle cell lymphoma.CANCER GENE THERAPY,25(5),129-140.
MLA Yang, Ping,et al."Genomic landscape and prognostic analysis of mantle cell lymphoma".CANCER GENE THERAPY 25.5(2018):129-140.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Ping]的文章
[Zhang, Weilong]的文章
[Wang, Jing]的文章
百度学术
百度学术中相似的文章
[Yang, Ping]的文章
[Zhang, Weilong]的文章
[Wang, Jing]的文章
必应学术
必应学术中相似的文章
[Yang, Ping]的文章
[Zhang, Weilong]的文章
[Wang, Jing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。